Botox vs Dysport: Clinical Differences, Dosing, and Economics for Injectors

The core distinction lies in the protein complex surrounding the active toxin. Botox carries a heavier protein coat (900 kDa), while Dysport's is lighter (500 kDa). This means Dysport diffuses more readily into surrounding muscle, spreading approximately 1–1.5 cm beyond the injection site versus Botox's tighter 0.5–1 cm radius. That diffusion advantage makes Dysport useful for large treatment areas (forehead, glabella) where you want broader muscle relaxation with fewer injections. Conversely, Botox's more localized spread suits precise work: periorbital lines, brow lift, or cases where you need to spare adjacent muscles.

Onset and Duration

Dysport typically shows visible softening within 24–48 hours, with full effect by day 7. Botox takes 3–7 days for initial effect and reaches plateau around day 14. For patient communication, this matters: Dysport patients see results sooner, which can improve satisfaction and referral perception. Both last roughly 12 weeks, though individual metabolism varies.

Unit Conversion and Dosing

This is where precision matters operationally. Dysport units are not 1:1 with Botox units. The standard conversion is approximately 3:1 or 4:1, meaning 1 unit of Botox ≈ 3–4 units of Dysport. A typical glabella dose of 20 Botox units converts to 60–80 Dysport units. Underdosing Dysport by using a 1:1 conversion is a common injector error that leads to poor results and patient dissatisfaction.

Why the Conversion Ratio Exists

The 3:1 to 4:1 ratio reflects differences in bioassay potency between the two products. Both toxins block acetylcholine at the neuromuscular junction, but Dysport's lighter protein complex allows faster diffusion and slightly lower per-unit potency relative to Botox's standardized reference. The ratio is not arbitrary—it's rooted in how each manufacturer's potency units are measured in mouse bioassays (LD50 testing). When you see "3:1 conversion," you're accounting for this bioassay difference, not just the diffusion profile.

In practice, some injectors find they prefer a 2.5:1 ratio for certain patients or areas, particularly if treating thin-skinned regions where Dysport's spread could cause unwanted relaxation. Conversely, high-volume practices treating thick musculature (male glabella, strong corrugators) may use a 4:1 or even 4.5:1 ratio. The conversion is a starting point, not a law; your clinical experience and patient anatomy should refine it.

Reconstitution and Stability

Dysport vials contain 300 or 500 units; Botox comes in 50, 100, and 200-unit vials. The 300-unit Dysport vial is popular for high-volume practices because it covers multiple treatment areas efficiently. However, Dysport's reconstitution window is tighter than Botox's: once mixed with saline, Dysport remains stable for 24 hours at room temperature, versus Botox's 4-week stability. This constraint matters operationally. If you're a lower-volume practice or have inconsistent patient flow, the 24-hour window creates waste risk. High-volume practices can move a 300-unit vial in 2–3 days, making that constraint irrelevant. Lower-volume practices may find the 100-unit Botox vial more practical despite higher per-unit cost.

Cost Structure and Economics

Dysport typically costs 15–25% less per unit than Botox at wholesale, but the unit-conversion math complicates the per-treatment comparison. A 20-unit Botox glabella treatment costs roughly $40–60 wholesale (depending on your rebate tier with Alle or Aspire); the equivalent 60–80 Dysport units runs $30–50. The savings are real but modest, usually $10–20 per treatment equivalent.

What moves the needle is loyalty rebates and volume tiers. AbbVie's Alle program and Galderma's Aspire Rewards both tier rebates based on annual spend. If you're already committed to Botox volume, switching to Dysport for marginal savings may cost you rebate tier status and negate the per-unit discount. Conversely, if you're building a practice or want to negotiate better terms, stocking both gives you leverage with your distributor.

Calculating True Per-Patient Cost

Don't compare Botox and Dysport on per-unit price alone. Calculate your actual cost per treatment by accounting for (1) wholesale unit cost after rebates, (2) the conversion ratio you use clinically, and (3) vial waste or shelf-life constraints. Example: if Botox costs you $0.12 per unit after rebates and you use 20 units per glabella treatment, your material cost is $2.40. If Dysport costs $0.08 per unit and you use 70 units (3.5:1 conversion), your material cost is $5.60—more expensive per treatment, despite cheaper per-unit pricing. Conversely, if you're treating a large forehead with Dysport's broader diffusion and can reduce total units needed, the economics flip. Track both products separately in your practice management software to see which is actually more profitable in your patient mix.

Clinical Scenarios: When to Choose Each

Choose Botox when:

• Precision is critical (lateral canthal lines, brow lift without frontalis involvement)
• Patient has had Botox before and expects predictable results
• You're treating a smaller practice with limited inventory turnover or inconsistent patient flow
• Your rebate tier with AbbVie justifies staying exclusive
• Treating thin-skinned areas where Dysport's diffusion could cause unintended relaxation of adjacent muscles

Choose Dysport when:

• Treating large surface areas (full forehead, bilateral glabella-frontalis complex) where broader diffusion reduces injection count
• Patient values rapid onset and wants to see results within 48 hours
• You have high patient volume and can move inventory before the 24-hour reconstitution window closes
• You're negotiating better pricing or want to reduce dependence on a single manufacturer
• Patient has previously had poor results with Botox and may respond better to Dysport's diffusion profile

Practical Stocking Strategy

Many high-volume practices stock both. Dysport's faster onset and broader diffusion make it the default for first-time patients seeking quick results; Botox handles retreats and precision cases. This dual approach also hedges supply-chain risk and gives you flexibility in rebate negotiations. Track your per-patient cost (including rebate recovery) and conversion rates separately for each product to know which is actually more profitable in your mix.

If you're converting an existing Botox patient to Dysport—whether for supply reasons or patient preference—communicate the conversion ratio clearly. A patient who received 20 units of Botox should expect to receive 60–80 units of Dysport for equivalent effect. Some practices include this in the patient chart or consent form to prevent confusion at follow-up visits.

Verify current pricing and rebate structures directly with your distributor or through Alle and Aspire, as these change quarterly.